Your shopping cart is currently empty

Methyl rosmarinate is a noncompetitive tyrosinase inhibitor isolated from Rabdosia serra, with an IC50 of 0.28 mM for mushroom tyrosinase. It exhibits antioxidative and antifungal activities, and also inhibits tyrosinase, α±-glucosidase, and matrix metalloproteinase-1 (MMP-1).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $68 | - | In Stock | |
| 5 mg | $168 | In Stock | In Stock | |
| 10 mg | $272 | - | In Stock | |
| 25 mg | $458 | - | In Stock | |
| 50 mg | $663 | - | In Stock | |
| 100 mg | $927 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $183 | - | In Stock |
| Description | Methyl rosmarinate is a noncompetitive tyrosinase inhibitor isolated from Rabdosia serra, with an IC50 of 0.28 mM for mushroom tyrosinase. It exhibits antioxidative and antifungal activities, and also inhibits tyrosinase, α±-glucosidase, and matrix metalloproteinase-1 (MMP-1). |
| Targets&IC50 | Tyrosinase:0.28 mM |
| In vitro | An initial microtiter dilution assay indicated activity of compounds against S. carnosus LTH1502, whereas esters with chain lengths, RA, n-Methyl rosmarinate (RE1), n-dodecyl rosmarinate (RE12), and n-octadecyl rosmarinate (RE18) were used in a time-kill assay S. carnosus LTH1502. Compounds were added at 0.75 mM in the log phase, 5 mM in the exponential phase, 10 mM in the stationary phase. RA had no effect in the lag and exponential phase but decreased cell counts during the stationary phase. In contrast, RE1 and RE12 decreased cell number in all three phase, will RE12 reducing counts most rapidly. Addition of RE18 did not affect regardless of the growth phase[1] |
| Molecular Weight | 374.34 |
| Formula | C19H18O8 |
| Cas No. | 99353-00-1 |
| Smiles | COC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1 |
| Relative Density. | 1.449 g/cm3 (Predicted) |
| Storage | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 160 mg/mL (427.42 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.